Lung Adenocarcinoma Clinical Trial
Official title:
Preoperative CT-based Radiomics Combined With Intraoperative Frozen Section is Predictive of Spread Through Air Space in Early Lung Adenocarcinoma
NCT number | NCT05400304 |
Other study ID # | RFSTAS |
Secondary ID | |
Status | Not yet recruiting |
Phase | |
First received | |
Last updated | |
Start date | July 1, 2022 |
Est. completion date | May 12, 2023 |
Verified date | June 2022 |
Source | Wuhan Union Hospital, China |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
a multifactorial model combining radiomics with frozen section analysis is a potential biomarker for assessing Spread Through Air Space during surgery, which can provide decision-making support to therapeutic planning for early-stage lung adenocarcinomas.
Status | Not yet recruiting |
Enrollment | 900 |
Est. completion date | May 12, 2023 |
Est. primary completion date | May 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. intraoperative frozen section diagnosis and final pathology diagnosis are available 2. preoperative standard non-enhanced CT is available 3. Pathologically confirmed Exclusion Criteria: 1. with a previous history of radiation therapy, chemotherapy or biopsy 2. the time interval between the CT examination and surgery was more than two weeks |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Wuhan Union Hospital, China |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sensitivity | Testing the sensitivity of Radiomics to predict STAS using the area under receiver operating characteristic curve | 24 hour before operation | |
Primary | Specificity | Testing the specificity of Radiomics to predict STAS using the area under receiver operating characteristic curve | 24 hour before operation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02898857 -
Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma
|
N/A | |
Completed |
NCT02127359 -
Whole-Exome Sequencing (WES) of Cancer Patients
|
||
Recruiting |
NCT01249066 -
Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma
|
N/A | |
Not yet recruiting |
NCT04482829 -
TCM in the Treatment of Lung Adenocarcinoma
|
N/A | |
Recruiting |
NCT04929041 -
Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative
|
Phase 2/Phase 3 | |
Terminated |
NCT04691375 -
A Study of PY314 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT02621333 -
Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma
|
Phase 2 | |
Active, not recruiting |
NCT02282267 -
Blood Detection of EGFR Mutation For Iressa Treatment
|
N/A | |
Not yet recruiting |
NCT01942629 -
Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas
|
N/A | |
Recruiting |
NCT01482585 -
Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy
|
N/A | |
Recruiting |
NCT03376737 -
Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT05537922 -
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
|
||
Recruiting |
NCT04937283 -
Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
|
N/A | |
Recruiting |
NCT06255197 -
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
|
||
Completed |
NCT02093000 -
A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma
|
N/A | |
Recruiting |
NCT04119024 -
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
|
Phase 1 | |
Terminated |
NCT04682431 -
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05736991 -
Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma
|
||
Enrolling by invitation |
NCT05136014 -
Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model
|
||
Terminated |
NCT05012397 -
Milademetan in Advanced/Metastatic Solid Tumors
|
Phase 2 |